DGKI — patent landscape

Top predicted compounds (top 20 by supporting neighbours, then confidence)

Compound	Confidence	Supporting neighbours
SCHEMBL21830991	1.00	3/20
SCHEMBL23293213	1.00	3/20
SCHEMBL29654799	1.00	3/20
SCHEMBL23293507	0.87	3/20
SCHEMBL23293148	0.84	3/20
SCHEMBL23293232	0.84	3/20
SCHEMBL23293265	0.84	3/20
SCHEMBL23293307	0.84	3/20
SCHEMBL23293196	0.83	3/20
SCHEMBL23293138	0.83	3/20
SCHEMBL23293147	0.81	3/20
SCHEMBL23293186	0.81	3/20
SCHEMBL30422200	0.81	3/20
SCHEMBL23293506	0.81	3/20
SCHEMBL23293193	0.79	3/20
SCHEMBL23293351	0.79	3/20
SCHEMBL23293353	0.79	3/20
SCHEMBL30422106	0.79	3/20
SCHEMBL23293169	0.78	3/20
SCHEMBL23293415	0.78	3/20

Clinical trials — most relevant to DGKI by text similarity (a relevance ranking, not an exhaustive list)

Trial	Phase	Status
The Effects of Eicosapentaenoic Acid (EPA), Gamma-Linolenic Acid (GLA) and Antioxidants in the Treatment of Sepsis	PHASE4	COMPLETED
Mitochondrial Oxidation and Insulin Resistance in Burn Patients Treated With Fenofibrate	PHASE2/PHASE3	WITHDRAWN
The G Protein-Coupled Receptor Kinase Type 2 Inhibitor Paroxetine as Adjunctive Therapy to Improve Insulin Sensitivity in Patients With Type 2 Diabetes Mellitus	PHASE3	UNKNOWN
Vitamin E and DHA-EE on NAFLD - Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Clinical Trial (PUVENAFLD)	PHASE2	COMPLETED
Theophylline Treatment for Pseudohypoparathyroidism - Children 2-12 Years Old	PHASE2	ACTIVE_NOT_RECRUITING
Effect of Gemfibrozil on Serum Glycosylphosphatidylinositol (GPI) Phospholipase D and Triglycerides	PHASE1	COMPLETED
Temsirolimus and Sorafenib in Advanced Hepatocellular Carcinoma	PHASE1	COMPLETED
Duality of Lipids: the Athlete's Paradox	nan	COMPLETED
Free Fatty Acid Induced Insulin Resistance	nan	COMPLETED
Tissue Lipids and Insulin Resistance	nan	WITHDRAWN
Skeletal Muscle Diacylglycerol and Sphingolipids - Impact of Localization and Species on Insulin Resistance in Humans	nan	COMPLETED
The Study Aims to Investigate the Effects of Oral Inositols on Insulin-resistance in Children With Obesity.	nan	UNKNOWN
A 12 Week, 3-Period Study to Evaluate the Effects of a Dietary Supplement on Lipid Metabolism	nan	COMPLETED
Glycine and Magnesium+Thiamine for the Treatment of Primary Ciliary Dyskinesia	nan	RECRUITING
Study of the Effect of a Nutritional Supplement on Microbiota, Metabolic Control, Inflammatory Profile, and Quality of Life in Patients With Polycystic Ovary Syndrome.	nan	RECRUITING
The Effect of Lowered Physical Activity on Insulin Sensitivity and Lipid and Glucose Metabolism	nan	COMPLETED
Role of Dairy Products in Weight Maintenance	nan	COMPLETED
Novel Inhibitors of Lipolysis in the Treatment of Lipid a Glucose Metabolism in Obstructive Sleep Apnea Syndrome	nan	UNKNOWN
Myoinositol Treatment and Asprosin Levels in PCOS	nan	COMPLETED
The Effects of Acetyl-L-Carnitine and Myo/Chiro-Inositol in Patients With PCOS	nan	COMPLETED
Study of Changes in Skeletal Muscle After Caloric Restriction	nan	ACTIVE_NOT_RECRUITING
The Role of Arachidonic Acid Metabolites, From Patients With Metabolic Syndrome	nan	UNKNOWN
Effect of Age on Glucose and Lipid Metabolism	nan	COMPLETED
Effect of Omega-3 Fatty Acids Supplementation on Hypertriglyceridemia in Pediatric Patients With Obesity.	nan	COMPLETED
Skeletal Muscle Mitochondrial Abnormalities and the Metabolic Syndrome in PAH	nan	COMPLETED
A Longitudinal Study on Short-term Effects of Gastric Bypass on Glucose Homeostasis in Obesity	nan	COMPLETED
Muscle Fat Compartments and Turnover as Determinant of Insulin Sensitivity	nan	COMPLETED
Effects of Fish Oils on Inflammation and Insulin Resistance	nan	COMPLETED
p-AKT Expression on Clinical Outcomes in Malignant Lymphoma	nan	COMPLETED
The Role of Programmed Death Ligand -1 (Pdl-1) in Lung Cancer	nan	COMPLETED

Related proteins — ESM-2 sequence neighbours (a DGKI binder may also engage these)

Protein	Name	Similarity
D3YWQ0	—	1.000	D3YWQ0 →
F1MAB7	—	1.000	F1MAB7 →
O08560	—	0.998	O08560 →
Q80UP3	—	0.998	Q80UP3 →
D3ZEY4	—	0.995	D3ZEY4 →
DGKZ	Diacylglycerol kinase zeta	0.995	landscape →
Q39017	—	0.995	Q39017 →
Q9FFN7	—	0.994	Q9FFN7 →
Q28314	—	0.992	Q28314 →
Q10024	—	0.992	Q10024 →
Q6P5E8	—	0.992	Q6P5E8 →
KAT8	Histone acetyltransferase KAT8	0.992	landscape →
Q03603	—	0.992	Q03603 →
Q8TBC3	—	0.992	Q8TBC3 →
Q5TKR9	—	0.992	Q5TKR9 →
Q9LRB0	—	0.992	Q9LRB0 →
Q8BMD7	—	0.992	Q8BMD7 →
KDM4B	Lysine-specific demethylase 4B	0.992	landscape →
A3KMV1	—	0.991	A3KMV1 →
A0JMQ9	—	0.991	A0JMQ9 →
Q8TDY4	—	0.991	Q8TDY4 →
Q8BJM7	—	0.990	Q8BJM7 →
P79290	—	0.990	P79290 →
Q17QK1	—	0.990	Q17QK1 →
G5EFD2	—	0.990	G5EFD2 →
KDM5B	Lysine-specific demethylase 5B	0.990	landscape →
Q1LYM3	—	0.990	Q1LYM3 →
P35546	—	0.990	P35546 →
O46080	—	0.989	O46080 →
Q80TM9	—	0.989	Q80TM9 →